Tag: bispecific antibody
-
Immune Complications Drive Higher Infection Risk in Advanced Myeloma Therapies
Overview: A New Frontier in Multiple Myeloma Treatment Chimeric Antigen Receptor (CAR T-cell) therapy and bispecific antibody (BsAb) therapy have transformed the management of advanced multiple myeloma (MM). These immunotherapies mobilize the patient’s own immune system to target and destroy malignant plasma cells, offering durable responses for many who have exhausted conventional therapies. Yet, with…
-
Addressing Infection Risks: Immune Complications in CAR T-Cell and Bispecific Antibody Therapies for Advanced Multiple Myeloma
Understanding the Shift in Multiple Myeloma Treatment Advances in multiple myeloma (MM) have ushered in a new era of immunotherapies, notably Chimeric Antigen Receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy. These approaches leverage the patient’s own immune system to target myeloma cells, often achieving deep and lasting responses where traditional therapies fall short.…